| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_563a341645c0d99f8a8534a3a36d956f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d620c46a864e66eee8bb717db16c55d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_996f98b58a6f301c080bd8862a8ab337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13750343c88f959a6df971819c1f17d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3eb6bb65bd8fc345221a6d3d0d1e3f6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
2003-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b19336be4a80a590f2d60ee7ff97ec51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d25091233e4255a3df5db49e47498a89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5114b3997d8236a979e3edbf39af271f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb65812e7d69ba9c3f2f3932012ddb46 |
| publicationDate |
2004-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004052375-A1 |
| titleOfInvention |
Novel therapeutical use of agonist ligands specific to lysophosphatidic acid receptor |
| abstract |
The present invention relates to a novel therapeutical use of agonist ligands specific to lysophosphatidic acid receptors. More particularly, the present invention relates to methods for treating diseases or disorders associated with excessive neutrophil accumulation in a subject, comprising administering LPA (1-acyl or 2-acyl lysophosphatidic acid) or the derivatives thereof to the subject. The agonist ligands for lysophosphatidic acid receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used 10 effectively in treatment of diseases or disorders associated with neutrophil accumulation and hyperactivity, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021205337-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017112861-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106170302-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106170302-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3135297-A4 |
| priorityDate |
2002-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |